Keryx Biopharmaceuticals, Inc. (KERX) Misses Q1 EPS by 7c

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q1 EPS of ($0.15), $0.07 worse than the analy t estimate of ($0.08). Revenue for the quarter came in at $10 million versus the consensus estimate of $9.91 million. At March 31, 2014, the Company had cash, cash equivalents, short-term investments and interest receivable of $155.1 million, as compared to $55.7 million at December 31, 2013.

"Over the past few months we have made significant strides in expanding our leadership team and building our commercial organization to support the launch of Zerenex™, pending potential approval," said Ron Bentsur, Chief Executive Officer of Keryx. "This work, along with the progress made on regulatory filings and clinical development, bring us closer to potentially providing Zerenex to patients in the U.S. and Europe."

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print